(SGGP) - The COVID-19 pandemic has posed challenges for healthcare systems worldwide, including in Vietnam, highlighting the need to improve community healthcare.
Mr. Peter Goldschmidt, CEO of STADA Group (left) and Mr. Chu Dang Trung, Director of the Department of Legal Affairs and Integration (middle) at the panel discussion
This key message was emphasized during the panel discussion “Enhancing community healthcare in Vietnam”, co-organized on August 9, 2023 in Ho Chi Minh City by the German Industry and Commerce in Vietnam (AHK Vietnam), STADA (Germany) and STADA Pymepharco.
According to speaker Mr. Chu Dang Trung, Director of the Department of Legal Affairs and Integration under the Drug Administration of Vietnam, Ministry of Health: “One of the lessons from COVID-19 is that to better care for public health, we must proactively build domestic pharmaceutical production capabilities.”
Quoting statistics, Mr. Trung noted: “In 2022, Vietnam’s pharmaceutical consumption reached nearly USD 7 billion, of which domestic production accounted for USD 3.5 billion, while imported medicines represented about USD 3.2 billion. In 2023, pharmaceutical consumption in Vietnam is projected to reach around USD 8 billion.”
He added: “The Vietnamese Government’s policy is to prioritize domestic pharmaceutical production, encourage enterprises to invest in EU-GMP certified manufacturing to help reduce drug prices, combat counterfeiting, and support the export of ‘Made in Vietnam’ pharmaceutical products to Europe.”
Speaker Mr. Peter Goldschmidt, CEO of STADA Group, shared: “The establishment of our EU-GMP certified pharmaceutical factory in Phu Yen aims to deliver high-quality Made-in-Vietnam products to improve healthcare for Vietnamese people, and support the development of the local pharmaceutical industry.”
Recognizing Vietnam’s strong potential, Mr. Goldschmidt further emphasized: “Through long-term collaboration, STADA aims to strengthen Vietnam’s pharmaceutical manufacturing capacity, ensure stable and reliable supply for both domestic and European markets, and create stable employment opportunities.”
